Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20097882 | 0.82 | HPGD (0.56) | HPGDTSHRKMT2ANOTUMTDP1 | |
| SCHEMBL21415510 | 0.82 | HPGD (0.56) | HPGDTSHRKMT2ANOTUMTDP1 | |
| SCHEMBL29249525 | 0.81 | HPGD (0.44) | HPGDTSHRKMT2ANOTUMTDP1 | |
| SCHEMBL29163286 | 0.78 | KMT2A (0.51) | HPGDTSHRKMT2AL3MBTL1CYP1A2 | |
| SCHEMBL8477888 | 0.78 | ALDH1A1 (0.51) | HPGDTSHRKMT2ATDP1L3MBTL1 | |
| SCHEMBL9205126 | 0.77 | HPGD (0.42) | HPGDTSHRKMT2ANOTUMTDP1 | |
| SCHEMBL15397124 | 0.74 | TDP1 (0.43) | HPGDTSHRKMT2ANOTUMTDP1 | |
| SCHEMBL29097030 | 0.73 | CASP1 (0.41) | HPGDTSHRNOTUMALDH1A1 | |
| SCHEMBL1598495 | 0.73 | HPGD (0.61) | HPGDKMT2ANOTUMTDP1L3MBTL1 | |
| SCHEMBL515976 | 0.72 | CYP1A2 (0.48) | HPGDTSHRKMT2ANOTUMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750032-B2 | Compounds and compositions as PPAR modulators | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-20090137591-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1843763-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM, LLC (BM) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006084176-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137591-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | PPARG, PPARD, PPARA | HPGD 590/4885TSHR 589/4885KMT2A 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.